Obesity and nosocomial infections

Journal of Hospital Infection

Volumn 85, Issue 1, 2013, Pages 8-16

  Huttunen, R ^a,b   Karppelin, M ^a,b   Syrjanen J ^a,b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Body mass index; Epidemic; Nosocomial infection; Obesity; Risk; Surgical

Indexed keywords

CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOTETAN; CEPHALOSPORIN DERIVATIVE; DORIPENEM; ERTAPENEM; LINEZOLID; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BODY MASS; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE ASSOCIATION; GASTROINTESTINAL SURGERY; HEART SURGERY; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INTENSIVE CARE; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MORBID OBESITY; ORTHOPEDIC SURGERY; PNEUMONIA; REVIEW; SURGICAL INFECTION; URINARY TRACT INFECTION; VASCULAR SURGERY;

EID: 84881664844     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2013.06.012     Document Type: Review

References (104)

1. Flegal K.M., Carroll M.D., Kit B.K., Ogden C.L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307:491-497.
2. Berghofer A., Pischon T., Reinhold T., Apovian C.M., Sharma A.M., Willich S.N. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008, 8:200.
3. Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world - a growing challenge. NEngl J Med 2007, 356:213-215.
4. Eber M.R., Laxminarayan R., Perencevich E.N., Malani A. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 2010, 170:347-353.
5. Anderson D.J., Kaye K.S., Classen D., et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 2008, 29(Suppl. 1):S51-S61.
6. Falagas M.E., Kompoti M. Obesity and infection. Lancet Infect Dis 2006, 6:438-446.
7. Fauci A.S., Morens D.M. The perpetual challenge of infectious diseases. NEngl J Med 2012, 366:454-461.
8. Falagas M.E., Koletsi P.K., Baskouta E., Rafailidis P.I., Dimopoulos G., Karageorgopoulos D.E. Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience. Epidemiol Infect 2011, 139:27-40.
9. Di Leo A., Piffer S., Ricci F., et al. Surgical site infections in an Italian surgical ward: a prospective study. Surg Infect (Larchmt) 2009, 10:533-538.
10. Dodds Ashley E.S., Carroll D.N., Engemann J.J., et al. Risk factors for postoperative mediastinitis due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004, 38:1555-1560.
11. Dowsey M.M., Choong P.F. Obese diabetic patients are at substantial risk for deep infection after primary TKA. Clin Orthop Relat Res 2009, 467:1577-1581.
12. Peel T.N., Dowsey M.M., Daffy J.R., Stanley P.A., Choong P.F., Buising K.L. Risk factors for prosthetic hip and knee infections according to arthroplasty site. JHosp Infect 2011, 79:129-133.
13. Dindo D., Muller M.K., Weber M., Clavien P.A. Obesity in general elective surgery. Lancet 2003, 361:2032-2035.
14. Bertakis K.D., Azari R. The influence of obesity, alcohol abuse, and smoking on utilization of health care services. Fam Med 2006, 38:427-434.
15. Bertakis K.D., Azari R. Obesity and the use of health care services. Obes Res 2005, 13:372-379.
16. Almond M.H., Edwards M.R., Barclay W.S., Johnston S.L. Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax 2013, 68:684-686.
17. Marti A., Marcos A., Martinez J.A. Obesity and immune function relationships. Obes Rev 2001, 2:131-140.
18. Nave H., Beutel G., Kielstein J.T. Obesity-related immunodeficiency in patients with pandemic influenza H1N1. Lancet Infect Dis 2011, 11:14-15.
19. Huttunen R., Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes (Lond) 2013, 37:333-340.
20. Littleton S.W. Impact of obesity on respiratory function. Respirology 2012, 17:43-49.
21. Huttunen R., Syrjänen J. Obesity and the outcome of infection. Lancet Infect Dis 2010, 10:442-443.
22. Dossett L.A., Dageforde L.A., Swenson B.R., et al. Obesity and site-specific nosocomial infection risk in the intensive care unit. Surg Infect (Larchmt) 2009, 10:137-142.
23. Bishara J., Farah R., Mograbi J., et al. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis 2013 May 20, [Epub ahead of print].
24. Kaye K.S., Marchaim D., Chen T.Y., et al. Predictors of nosocomial bloodstream infections in older adults. JAm Geriatr Soc 2011, 59:622-627.
25. Silber J.H., Rosenbaum P.R., Kelz R.R., et al. Medical and financial risks associated with surgery in the elderly obese. Ann Surg 2012, 256:79-86.
26. Schultz M.J., Spronk P.E. Overweight in ICU patients: is the body mass index reliable?. Chest 2005, 127:683-684. author reply 684.
27. Beldi G., Bisch-Knaden S., Banz V., Muhlemann K., Candinas D. Impact of intraoperative behavior on surgical site infections. Am J Surg 2009, 198:157-162.
28. Greenblatt D.Y., Rajamanickam V., Mell M.W. Predictors of surgical site infection after open lower extremity revascularization. JVasc Surg 2011, 54:433-439.
29. Wick E.C., Hirose K., Shore A.D., et al. Surgical site infections and cost in obese patients undergoing colorectal surgery. Arch Surg 2011, 146:1068-1072.
30. Healy L.A., Ryan A.M., Sutton E., et al. Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. Int J Colorectal Dis 2010, 25:1293-1299.
31. Okabayashi T., Nishimori I., Yamashita K., et al. Risk factors and predictors for surgical site infection after hepatic resection. JHosp Infect 2009, 73:47-53.
32. Giles K.A., Hamdan A.D., Pomposelli F.B., Wyers M.C., Siracuse J.J., Schermerhorn M.L. Body mass index: surgical site infections and mortality after lower extremity bypass from the National Surgical Quality Improvement Program 2005-2007. Ann Vasc Surg 2010, 24:48-56.
33. Spelman D.W., Russo P., Harrington G., et al. Risk factors for surgical wound infection and bacteraemia following coronary artery bypass surgery. Aust NZ J Surg 2000, 70:47-51.
34. Göl M.K., Karahan M., Ulus A.T., et al. Bloodstream, respiratory, and deep surgical wound infections after open heart surgery. JCard Surg 1998, 13:252-259.
35. Ahmed D., Cheema F.H., Ahmed Y.I., et al. Incidence and predictors of infection in patients undergoing primary isolated coronary artery bypass grafting: a report from a tertiary care hospital in a developing country. JCardiovasc Surg (Torino) 2011, 52:99-104.
36. Al-Zaru I.M., Ammouri A.A., Al-Hassan M.A., Amr A.A. Risk factors for deep sternal wound infections after cardiac surgery in Jordan. JClin Nurs 2010, 19:1873-1881.
37. Sharma M., Fakih M.G., Berriel-Cass D., Meisner S., Saravolatz L., Khatib R. Harvest surgical site infection following coronary artery bypass grafting: risk factors, microbiology, and outcomes. Am J Infect Control 2009, 37:653-657.
38. Olsen M.A., Sundt T.M., Lawton J.S., et al. Risk factors for leg harvest surgical site infections after coronary artery bypass graft surgery. JThorac Cardiovasc Surg 2003, 126:992-999.
39. Baillot R., Frechette E., Cloutier D., et al. Surgical site infections following transcatheter apical aortic valve implantation: incidence and management. JCardiothorac Surg 2012, 7:122.
40. Greenblatt D.Y., Kelly K.J., Rajamanickam V., et al. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol 2011, 18:2126-2135.
41. Su Z., Koga R., Saiura A., Natori T., Yamaguchi T., Yamamoto J. Factors influencing infectious complications after pancreatoduodenectomy. JHepatobiliary Pancreat Sci 2010, 17:174-179.
42. 2) patients? An NSQIP data analysis. Surg Obes Relat Dis 2010, 7:452-458.
43. Merkow R.P., Bilimoria K.Y., McCarter M.D., Bentrem D.J. Effect of body mass index on short-term outcomes after colectomy for cancer. JAm Coll Surg 2009, 208:53-61.
44. Gervaz P., Bandiera-Clerc C., Buchs N.C., et al. Scoring system to predict the risk of surgical-site infection after colorectal resection. Br J Surg 2012, 99:589-595.
45. Bochicchio G.V., Joshi M., Bochicchio K., Nehman S., Tracy J.K., Scalea T.M. Impact of obesity in the critically ill trauma patient: a prospective study. JAm Coll Surg 2006, 203:533-538.
46. Xing D., Ma J.X., Ma X.L., et al. Amethodological, systematic review of evidence-based independent risk factors for surgical site infections after spinal surgery. Eur Spine J 2013, 22:605-615.
47. Namba R.S., Inacio M.C., Paxton E.W. Risk factors associated with surgical site infection in 30 491 primary total hip replacements. JBone Joint Surg Br 2012, 94:1330-1338.
48. Pull Ter Gunne A.F., Hosman A.J., Cohen D.B., et al. Amethodological systematic review on surgical site infections following spinal surgery: Part 1: Risk factors. Spine (Phila Pa 1976) 2012, 37:2017-2033.
49. McCalden R.W., Charron K.D., Macdonald S.J., Bourne R.B., Naudie D.D. Does morbid obesity affect the outcome of total hip replacement?: an analysis of 3290 THRs. JBone Joint Surg Br 2011, 93:321-325.
50. Linam W.M., Margolis P.A., Staat M.A., et al. Risk factors associated with surgical site infection after pediatric posterior spinal fusion procedure. Infect Control Hosp Epidemiol 2009, 30:109-116.
51. Barbut F., Petit J.C. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001, 7:405-410.
52. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
53. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
54. Hopkins M.J., Macfarlane G.T. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. JMed Microbiol 2002, 51:448-454.
55. Serrano P.E., Khuder S.A., Fath J.J. Obesity as a risk factor for nosocomial infections in trauma patients. JAm Coll Surg 2010, 211:61-67.
56. Haley V.B., Van Antwerpen C., Tsivitis M., et al. Risk factors for coronary artery bypass graft chest surgical site infections in New York State, 2008. Am J Infect Control 2012, 40:22-28.
57. Fezeu L., Julia C., Henegar A., et al. Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis. Obes Rev 2011, 12:653-659.
58. Fischer J.P., Nelson J.A., Mirzabeigi M.N., et al. Prophylactic muscle flaps in vascular surgery. JVasc Surg 2012, 55:1081-1086.
59. Tipton A.M., Cohen S.A., Chelmow D. Wound infection in the obese pregnant woman. Semin Perinatol 2011, 35:345-349.
60. Esteban A., Frutos-Vivar F., Anzueto A. Impact of body weight on critically ill patients: a heavy load!!. Intensive Care Med 2008, 34:1964-1965.
61. Hogue C.W., Stearns J.D., Colantuoni E., et al. The impact of obesity on outcomes after critical illness: a meta-analysis. Intensive Care Med 2009, 35:1152-1170.
62. Sakr Y., Madl C., Filipescu D., et al. Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med 2008, 34:1999-2009.
63. Edmonds R.D., Cuschieri J., Minei J.P., et al. Body adipose content is independently associated with a higher risk of organ failure and nosocomial infection in the nonobese patient postinjury. JTrauma 2011, 70:292-298.
64. Zahr F., Genovese E., Mathier M., et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg 2011, 92:1420-1426.
65. Bercault N., Boulain T., Kuteifan K., Wolf M., Runge I., Fleury J.C. Obesity-related excess mortality rate in an adult intensive care unit: a risk-adjusted matched cohort study. Crit Care Med 2004, 32:998-1003.
66. Frat J.P., Gissot V., Ragot S., et al. Impact of obesity in mechanically ventilated patients: a prospective study. Intensive Care Med 2008, 34:1991-1998.
67. Wurzinger B., Dunser M.W., Wohlmuth C., et al. The association between body-mass index and patient outcome in septic shock: a retrospective cohort study. Wien Klin Wochenschr 2010, 122:31-36.
68. Bamgbade O.A., Rutter T.W., Nafiu O.O., Dorje P. Postoperative complications in obese and nonobese patients. World J Surg 2007, 31:556-560. discussion 561.
69. Bochicchio G.V., Joshi M., Shih D., Bochicchio K., Tracy K., Scalea T.M. Reclassification of urinary tract infections in critically ill trauma patients: a time-dependent analysis. Surg Infect (Larchmt) 2003, 4:379-385.
70. Johnson S.R., Kolberg B.H., Varner M.W., Railsback L.D. Maternal obesity and pregnancy. Surg Gynecol Obstet 1987, 164:431-437.
71. Acosta C.D., Bhattacharya S., Tuffnell D., Kurinczuk J.J., Knight M. Maternal sepsis: a Scottish population-based case-control study. Br J Obstet Gynaecol 2012, 119:474-483.
72. Sebire N.J., Jolly M., Harris J.P., et al. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord 2001, 25:1175-1182.
73. Sen S., Iyer C., Klebenov D., Histed A., Aviles J.A., Meydani S.N. Obesity impairs cell mediated immunity during the second trimester of pregnancy. Am J Obstet Gynecol 2013, 208:139.e1-139.e8.
74. Jain R., Chung S.M., Jain L., et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011, 90:77-89.
75. Roe J.L., Fuentes J.M., Mullins M.E. Underdosing of common antibiotics for obese patients in the ED. Am J Emerg Med 2012, 30:1212-1214.
76. Hall R.G., Payne K.D., Bain A.M., et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 2008, 121:515-558.
77. Falagas M.E., Karageorgopoulos D.E. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010, 375:248-251.
78. Janson B., Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis 2012, 25:634-649.
79. Forse R.A., Karam B., MacLean L.D., Christou N.V. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989, 106:750-756. discussion 756-757.
80. Toma O., Suntrup P., Stefanescu A., London A., Mutch M., Kharasch E. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg 2011, 113:730-737.
81. Edmiston C.E., Krepel C., Kelly H., et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels?. Surgery 2004, 136:738-747.
82. Ho V.P., Nicolau D.P., Dakin G.F., et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt) 2012, 13:33-37.
83. Itani K.M., Jensen E.H., Finn T.S., Tomassini J.E., Abramson M.A. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect (Larchmt) 2008, 9:131-137.
84. Gulluoglu B.M., Guler S.A., Ugurlu M.U., Culha G. Efficacy of prophylactic antibiotic administration for breast cancer surgery in overweight or obese patients: a randomized controlled trial. Ann Surg 2013, 257:37-43.
85. Lodise T.P., Lomaestro B., Graves J., Drusano G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
86. Deman H., Verhaegen J., Willems L., Spriet I. Dosing of piperacillin/tazobactam in a morbidly obese patient. JAntimicrob Chemother 2012, 67:782-783.
87. Erstad B.L. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004, 30:18-32.
88. Kees M.G., Weber S., Kees F., Horbach T. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. JAntimicrob Chemother 2011, 66:2330-2335.
89. Cook A.M., Martin C., Adams V.R., Morehead R.S. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother 2011, 55:3240-3243.
90. Stein G.E., Schooley S.L., Peloquin C.A., et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005, 39:427-432.
91. Newman D., Scheetz M.H., Adeyemi O.A., et al. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007, 41:1734-1739.
92. Roberts J.A., Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013, 41:489-495.
93. Koselke E., Kraft S., Smith J., Nagel J. Evaluation of the effect of obesity on voriconazole serum concentrations. JAntimicrob Chemother 2012, 67:2957-2962.
94. Harrop J.S., Styliaras J.C., Ooi Y.C., Radcliff K.E., Vaccaro A.R., Wu C. Contributing factors to surgical site infections. JAm Acad Orthop Surg 2012, 20:94-101.
95. Debarge R., Nicolle M.C., Pinaroli A., Ait Si Selmi T., Neyret P. [Surgical site infection after total knee arthroplasty: a monocenter analysis of 923 first-intention implantations.]. Rev Chir Orthop Reparatrice Appar Mot 2007, 93:582-587.
96. Alexander J.W., Rahn R., Goodman H.R. Prevention of surgical site infections by an infusion of topical antibiotics in morbidly obese patients. Surg Infect (Larchmt) 2009, 10:53-57.
97. Alexander J.W., Rahn R. Prevention of deep wound infection in morbidly obese patients by infusion of an antibiotic into the subcutaneous space at the time of wound closure. Obes Surg 2004, 14:970-974.
98. Fujiki M., Guta C.G., Lemmens H.J., Brock-Utne J.G. Is it more difficult to cannulate the right internal jugular vein in morbidly obese patients than in nonobese patients?. Obes Surg 2008, 18:1157-1159.
99. McLaws M.L., Burrell A.R. Zero risk for central line-associated bloodstream infection: are we there yet?. Crit Care Med 2012, 40:388-393.
100. Trick W.E., Miranda J., Evans A.T., Charles-Damte M., Reilly B.M., Clarke P. Prospective cohort study of central venous catheters among internal medicine ward patients. Am J Infect Control 2006, 34:636-641.
101. Ottestad E., Schmiessing C., Brock-Utne J.G., Kulkarni V., Parris D., Brodsky J.B. Central venous access in obese patients: a potential complication. Anesth Analg 2006, 102:1293-1294.
102. 13C-octanoic acid breath test. Diabetes Obes Metab 2004, 6:264-270.
103. Morrish G.A., Pai M.P., Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011, 7:697-706.
104. Pai M.P., Bearden D.T. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007, 27:1081-1091.